Advice
Following a full submission.
Posaconazole (Noxafil®) is accepted for use for use within NHS Scotland for the treatment of adults with specific invasive fungal infections refractory to or intolerant of specified antifungal agents.
The evidence to support the licensed use of posaconazole is limited to one open-label, non- comparative study mainly in patients refractory to treatment with amphotericin.
Download detailed advice67KB (PDF)
Medicine details
- Medicine name:
- Posaconazole 40mg/ml Oral Suspension (Noxafil)
- SMC ID:
- 256/06
- Indication:
- Specific invasive fungal infections
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 05 May 2006